These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 29409974

  • 1. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
    Lyu H, Wang S, Huang J, Wang B, He Z, Liu B.
    Cancer Lett; 2018 Apr 28; 420():97-108. PubMed ID: 29409974
    [Abstract] [Full Text] [Related]

  • 2. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
    Li X, Xu Y, Ding Y, Li C, Zhao H, Wang J, Meng S.
    Mol Cancer; 2018 Aug 02; 17(1):113. PubMed ID: 30068375
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
    Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B.
    Breast Cancer Res; 2013 Aug 02; 15(5):R101. PubMed ID: 24168763
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation.
    Zhao Z, Li R, Sha S, Wang Q, Mao W, Liu T.
    Cancer Biol Ther; 2014 Oct 02; 15(10):1404-12. PubMed ID: 25046105
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H, Huang J, Edgerton SM, Thor AD, He Z, Liu B.
    Int J Clin Exp Pathol; 2015 Oct 02; 8(6):6143-56. PubMed ID: 26261492
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
    Yang L, Li Y, Shen E, Cao F, Li L, Li X, Wang X, Kariminia S, Chang B, Li H, Li Q.
    Int J Oncol; 2017 Nov 02; 51(5):1553-1562. PubMed ID: 29048656
    [Abstract] [Full Text] [Related]

  • 16. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
    Trono P, Di Modugno F, Circo R, Spada S, Di Benedetto A, Melchionna R, Palermo B, Matteoni S, Soddu S, Mottolese M, De Maria R, Nisticò P.
    Oncogene; 2016 Feb 18; 35(7):887-96. PubMed ID: 25961924
    [Abstract] [Full Text] [Related]

  • 17. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
    Wu Y, Zhang Y, Wang M, Li Q, Qu Z, Shi V, Kraft P, Kim S, Gao Y, Pak J, Youngster S, Horak ID, Greenberger LM.
    Mol Cancer Ther; 2013 Apr 18; 12(4):427-37. PubMed ID: 23395887
    [Abstract] [Full Text] [Related]

  • 18. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
    Way TD, Kao MC, Lin JK.
    J Biol Chem; 2004 Feb 06; 279(6):4479-89. PubMed ID: 14602723
    [Abstract] [Full Text] [Related]

  • 19. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.
    Leivonen SK, Sahlberg KK, Mäkelä R, Due EU, Kallioniemi O, Børresen-Dale AL, Perälä M.
    Mol Oncol; 2014 Feb 06; 8(1):93-104. PubMed ID: 24148764
    [Abstract] [Full Text] [Related]

  • 20. MiR-155-3p acts as a tumor suppressor and reverses paclitaxel resistance via negative regulation of MYD88 in human breast cancer.
    Zhang L, Chen T, Yan L, Xu H, Wang Y, Li Y, Wang H, Chen S, Wang W, Chen C, Yang Q.
    Gene; 2019 Jun 05; 700():85-95. PubMed ID: 30878390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.